ArticleCureus2025
Encephaloduroarteriosynangiosis for the Treatment of Cerebral Arteriovenous Malformations in the Pediatric Population.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arteriovenous malformations (AVMs) in the pediatric population are rare but represent a critical cause of spontaneous intracranial hemorrhage. Here we present the case of an 11-year-old boy who developed acute-onset left-sided weakness, slurred speech, and transient hemiparesis. While initial laboratory findings were unremarkable, brain magnetic resonance imaging revealed a large right cerebral AVM. Cerebral angiography confirmed this finding, showing a Spetzler-Martin grade V AVM, supplied by the middle, anterior, and posterior cerebral arteries. The patient was treated using a multimodal approach, including embolization and encephaloduroarteriosynangiosis (EDAS). Postoperatively, he experienced transient worsening of hemiparesis of unknown etiology, which gradually improved. Long-term follow-up demonstrated improved motor function with persistent mild left-sided weakness. This case highlights the significance of multimodal management in high-grade pediatric AVMs. This particular includes the utility of EDAS, originally developed for moyamoya disease, in mitigating ischemia by promoting collateral neovascularization and thus improving neurological symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.